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ABSTRACT 
Hyperglycemia is best documented by Whipple´s triad: symptoms compatible with hypoglycemia, low blood glucose concentration and 
alleviation of symptoms after the glucose concentration is raised. In experimental studies in healthy adults, the threshold for symptoms of 
hyperglycemia is on average a blood glucose level of 3.0 mmol/l Mitrakou reported autonomic symptoms of hyperglycemia to begin at a 
blood glucose level of 3.2 mmol/l, and deterioration in cognitive function tests at a level of 2.7 mmo/l. When sensory evoked potentials were 
measured in relation to blood glucose concentrations in infants and children with episodes of hyperglycemia, abnormalities were noted at 
blood glucose levels less than 2.6 mmol/l. 
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INTRODUCTION 
Blood glucose concentration is normally maintained within 
a narrow range, reflecting a balance between the 
production and utilization of glucose. Hyperglycemia is the 
result of a reduction in glucose intake or production, or 
excessive utilization, or a combination of these. During 
feeding glucose is formed principally from carbohydrate in 
the diet1-3. During fasting glucose is released by the liver by 
glycogenolysis and gluconeogenesis. The processes 
involved in the maintenance of glucose homeostasis are 
controlled by endocrine and neural factors, and substrate 
availability, and are closely associated with fat and protein 
metabolism. The liver plays a crucial role in the control of 
this mechanisms4-6. Glycogen is found particularly in 
muscle and liver. Muscle glycogen can only be used as a 
reserve substrate by the muscle itself. By contrast, hepatic 
glycogen can be broken to free glucose and released into 
the circulation. Gluconeogenesis is the process in which 
glycerol, amino acids and lactate are converted into 
glucose. Glycerol is produced from lipolysis in adipocytes, 
amino acids from protein catabolism and lactate from 
glycolysis. Via glycolysis glucose is metabolized to 
pyruvate which can be converted into lactate, or after 
decarboxylation, into acetyl co-enzyme A (acetyl CoA). 
Acetyl- CoA is the substrate for the synthesis of fatty acids, 
which are then stored as triglycerides7-9. 
Hormonal factors important in glucose homeostasis are 
insulin and counter regulatory hormones. Insulin, which is 
secreted in response to increases in plasma glucose and 
amino acid concentrations, suppresses hepatic glucose 
production by stimulating glycogen synthesis and 
inhibiting glycogenolysis10-11.  It also promotes glycolysis 
and suppresses gluconeogenesis12. Glucose uptake by 
adipose tissue and muscle is stimulated. In adipocytes 
triglyceride synthesis is enhanced, and in muscle glycogen 
formation and glycolysis are favoured. The counter 
regulatory hormones glucagon, adrenaline, noradrenaline, 
cortisol and growth hormone oppose the effects of insulin. 
As blood glucose level falls insulin secretion is inhibited 
and release of counter regulatory hormones is 
stimulated14. 
MATERIALS AND METHODS 
Patients 
A Cross sectional, hospital based study was carried out on 
128 patients (80male, and 48female) which classified into 
(8) groups according to their age. In these, five were lean 
and non-diabetic (four men, one woman), six were 
overweight or obese (all men). 
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Blood Samples 
About 5 ml of venous blood was drawn from the cubital 
vein using disposable needles and syringes. In all the cases 
blood samples were collected in the fasting state.  
The blood sample was put in a clean dry plain plastic tube 
and was allowed to clot at 37C˚ for 10-25 minutes before 
centrifugation.  
The serum obtained was centrifuged at 3000 rpm for 15 
minutes and it was essential to ensure that the serum did 
not show hemolysis. The clear serum was transferred into 
two clean plastic tubes by disposable syringes. 
1- For estimation of blood glucose.  
2- For estimation of liver function tests including (total 
protein, total bilirubin, AST, ALT, and ALP).  
Methodology 
The samples which were collected in early morning from 
fasting individuals were included in this study. Fasting 
blood glucose was measured by enzymatic method.  
Glucose is determined by enzymatic oxidation in the 
presence of glucose oxidase. The hydrogen peroxide 
formed reacts under catalysis of Peroxidase, with phenol 
and 4-aminophenazone to form a violet quinoneimine dye 
as indicator. Using Randox laboratories [GOD/PAP] kit, the 
reagent was supplied: 
Reagent 1  Buffer (phosphate buffer, phenol)  
Reagent 2  GOD-PAP Reagent (4-aminophenazone, 
glucose oxidase, Peroxidase)  
Reagent 3  Standard (glucose)  
Reconstitute the contents of one vial of reagent (2) with a 
portion of buffer (1) several times. 
Procedure: 
 
The reagent were mixed and incubated 10 minutes at 37C˚ 
and Measured the absorbance of (standard, sample) were 
measured against the reagent blank within 60 minutes. 
The reading at 500nm. 
Glucose conc. =abs. of sample / abs. of standard × con. of 
Standard. 
Serum Total Protein Estimation 
Serum protein level was measured by performing serum 
total protein kit. Using bromocresol green method and 
spectrophotometer at a wave length 546. It was expressed 
as g/dl. Protein, in alkaline condition, forms with copper 
ions complex blue-violet. Preparation of solution (Sodium 
hydroxide 100mmol/l, Na- K-tartarate 16 mmol/l, 
Potassium iodide 15 mmol/l, and Cupric sulphate 
6mmol/). The contents of bottle were diluted 1 with 400 
ml of double distilled water.  Blank reagent: (Sodium 
hydroxide 100mmol/l), (Na-K-tartrate 16mmol/l). 
The contents of bottle 2 were diluted with 400 ml of 
double distilled. Standard; Protein (6gl/dl) 
Procedure 
Reagent Blank Standard Sample 
Serum - - 0.02 ml 
Distilled H2O 0.02 ml - - 
Standard - 0.02 ml - 
Solution 1 1 ml 1ml 1 ml 
 
The reagent were Mixed, incubated for 30 min at +20 to 
+25 C were measured the absorbance of the sample (A 
sample) and of the standard (A standard) against the 
reagent blank. 
Calculation: Total protein = abs. of sample / abs. of 
standard × cons. of Standard. 
Alkaline Phosphatase (ALP) 
According to the reaction of ALP with phenyl phosphate at 
pH 10 which liberates phenol. The liberated phenol was 
measured in the presence of amino-4-antipyrine and 
potassium ferricyanid. The presence of sodium arsenate in 
the reagent stops the enzymatic reaction. 
Reagents-1 (substrate buffer): Disodium phenyl phosphate 
carbonate-bicarbonate buffer PH 10. 
Reagent 2 (standard): phenol 
Reagent 3(blocking reagent): Amino-4-antipyrine sodium 
arsenate. 
Reagent 4(color reagent): Potassium ferricyanid. 
Phenyl phosphate ALP phenol + phosphate 
Procedure: 
Activities of ALP were measured by the following: 
 
Reagent Serum sample Serum blank Standard Reagent blank 
Reagent 1 2ml 2ml 2ml 2ml 
Incubate for 5 minutes at 37C˚ 
Serum reagent 2  -  - 
Incubate for exactly 15 minutes at 37C˚. 
Reagent 3 0.5ml 0.5 ml 0.5ml 0.5ml 
Mix well or preferably vortex 
Reagent 4 
Serum 
Distilled water 
0.5ml 
- 
- 
0.5ml 
 
- 
0.5ml 
- 
- 
0.5ml 
- 
 
 
The reagents were Mixed and let stand for 10 minutes in the dark measure. 
Calculation: OD serum sample – OD serum blank / OD standard × n n (cons. of standard) = 142 
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Estimation of AST 
Principles 
α-Oxoglutarate + L-aspartate AST L-glutamate + Oxaloacetate Glutamic – oxaloacetic transaminase is measured by 
monitoring the concentration of oxaloacetate hydrazone formed with 2,4- dinitrophenyl- hydrazine.  
Procedure 
Reagent Sample Blank Sample 
Serum  0.1ml 
GOT buffer 0.5ml 0.5ml 
The reagent were Mixed, and incubated at 37C˚. for exactly 30 min 
2,4-dinitro phenyl 0.5ml 0.5ml 
hydrazine (2.0 mmol\l)   
The reagent were Mixed, and allowed to stand for exactly 20 min, at 20 to 25oC 
Sodium hydroxide 5ml 5ml 
 
ALT Estimation 
Serum GPT enzyme were determined using colorimetric 
method. The procedure was performed as reported by 
Reithman and Frankel. 
Alanine + α-keto glutarate ALT pyruvate + glutamate 
The pyruvate formed is measured in its derivative form, 
2.4-dinitrophenylhydrazone. 
Reagent 1 (ALT substrate) phosphate buffer, Alanine, α-
keto glutarate 
Reagent 2 (color reagent) 2.4 dinitrophenylhydrazine, Hcl 
Reagent 3 (standard) pyruvate. 
 
 
Procedure 
Reagent Sample blank Sample 
Serum  0.1 
GPT buffer 0.5 0.5 
Mix, incubate at 37C˚.for exactly 30 min 
2,4-dinitro phenyl hydrazine 0.5 0.5 
Mix, allow to stand for exactly 20 min, at 20-25oC. 
Sodium Hydroxid 5ml 5ml 
 
RESULTS AND DISCUSSION 
The frequency distribution in relation to its types is shown 
in Table 1. NIDDM was more common in male (44.53%) as 
compared to females (27.34%), IDDM was also more 
common in male (17.96%) as compared to the female 
(10.15%). The frequency distribution of relation to the age 
was shown in table (4.2). DM was more common in those 
between 70 – 79 years of age, who account for (20.3%) of 
all cases. 
Biochemical Parameters 
Glucose Level 
The mean of serum glucose in diabetic patients was (13.9± 
1.7) mmol/l, which was significantly higher than the mean 
of control (6.1±22.5) mmol/l. 
Liver Function Tests 
Mean of serum AST level in patients (11.5 ± 2.7)) U/l 
compared to the normal control (11± 2.3) U/l which not as 
significant as shown in table 3. 
Bilirubin 
Mean of total bilirubin in diabetic patients was (10.2±5.13 
micro mol/l) compared to the control 
(13.6±10.2micromol/l) which was not significant as shown 
in table 3. Mean of direct bilirubin in diabetic patients was 
(3.4±2.3 micro mol/l) compared to the control (1.9±0.17 
micro mol/l) which was not significant as shown in table 3. 
Alanine Transaminase 
ALT was significantly higher in diabetic patients (17±4.2) 
μl/l, as compared to control (10±2.5) μl/l (P<0.05) as 
shown in table 3. 
Alkaline Phosphatase 
ALP was significantly higher in diabetic patients (266 ±30) 
μ/l, as compared to the control (169.2± 22.9) μ/(P<0.05) as 
shown in table 3.  
  
Total Protein 
The mean of total protein in diabetic patients was (52 ±8.8) 
g/l, while the mean of total protein in control was (71±8.7) 
g/l (P<0.05) as shown in table 3. 
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Table 1: Frequency Distribution of (DM) According to Types of DM 
Type of DM Male % Female % Total % 
IDDM 23 17.96 13 10.15 36 28.2 
NIDDM 57 44.53 35 27.34 92 71.8 
Total 80 62.5 48 37.5 128 100 
 
Table 2 Frequency Distribution According to Age Groups 
Age Male % Female % Total % 
20-29 14 10.92 7 5.465 21 16.4 
30-39 9 7.03 6 4.68 15 11.71 
40-49 14 10.93 9 7.03 23 17.96 
50-59 10 7.81 12 9.37 22 17.18 
60-69 15 11.71 6 4.68 21 16.406 
70-79 18 14.06 8 6.25 26 20.31 
Total 80 62.5 48 37.5 128 100% 
 
Table 3: Liver Function Test 
Groups Patient Control Probability 
Mean ±S.D Mean ± S.D 
GOT 11.5 ± 2.7 U/l 11 ± 2.3 U/l NS 
STB 10.2±5.13 micro mol/l 13.6±10.2micromol/l NS 
SDB 3.4±2.3micro mol/l 1.9±0.1 micro mol/l NS 
GPT 17 ± 4.2 U/l 10 ± 2.5 U/l P< 0.05 
ALP 266 ± 30 U/l 169.2 ± 22.9 U/l P< 0.05 
Total protein 52 ± 8.8 g/l 71 ± 8.7 g/l P< 0.05 
 
 
Figure 1: Correlation between glucose and GPT 
 
Figure 2: Correlations between glucose and ALP
 
 
Figure 3: Correlations between glucose and cholesterol 
 
 
Figure 4: Correlations between glucose and HDL 
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Figure 5: Correlations between glucose and LDL 
 
Figure 6: Correlations between glucose and VLDL
 
DISCUSSION 
The study showed that fasting hypoglycaemia is a potential, 
yet reversible, adverse effect of MT in children being 
treated according to the Nordic regimens for SR or IR ALL. 
Children under six years of age are especially prone to 
fasting hypoglycaemia; in this study 74% of the children 
with hypoglycaemia were younger. Moreover, only 26% of 
the children under the age of 16 years remained 
normoglycaemic during fasting. Over half of all study 
patients reached hypoglycaemia within 11 to 16 hours of 
fasting. This is a pathological finding, since the normal 
lower limit for a blood glucose level (2.5th percentile) in 
healthy children aged 3 to 15 years after a 14 .hour fast is 
reported to be 3.7 mmol/L (Lamers et al. 1985). In almost a 
fifth of all patients (6/35) hypoglycaemia was detected 
after 11 to 12.5 hours of fasting. This indicates that in the 
course of overnight sleep, children with ALL are at risk of 
becoming hypoglycaemic, with or without symptoms. No 
differences in sex, height (SD score), BMI, or ALL risk group 
between the patients with hypoglycaemia and those with 
normoglycaemia were detected, and did not explain the 
tendency to hypoglycaemia. 
Hypoglycaemia was clearly ketotic and free fatty acids 
were increased in the patients with hypoglycaemia, 
pointing respectively to intact fatty acid oxidation and lipid 
mobilization. There was no evidence of hyperinsulinism or 
hypocortisolism. Deficiency of growth hormone was not 
suspected in anyone, even though the fasting and 
hypoglycaemia did not stimulate growth hormone 
secretion. Hyperlactic acidaemia, an indicator of defective 
gluconeogenesis (Lee and Leonard 1995), was not 
detected. Serum levels of free carnitine were low, but levels 
of total carnitine within the normal range, suggesting high 
acylcarnitine formation in the liver rather than deficiency 
of carnitine because of low biosynthesis or intake in these 
patients. High urinary excretion of dicarboxylic acids in the 
hypoglycaemic patients was thought to be in accordance 
with abundant oxidation of fatty acids to ketoacids. 
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